Skip to main content
SpringerLink
Log in

Teduglutide: A Review in Short Bowel Syndrome

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Subcutaneous teduglutide (Revestive®), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the EU for the treatment of short bowel syndrome (SBS) in patients aged ≥1 year who are stable following a period of postsurgical intestinal adaptation. In a phase III trial in adults with SBS intestinal failure (IF) dependent on parenteral support (PS), a significantly greater proportion of teduglutide 0.05 mg/kg/day than placebo recipients achieved a ≥20% reduction in weekly PS volume from baseline to week 20 and maintained it to week 24. The proportion of patients who had a reduction in one or more days on PS was also significant with teduglutide compared with placebo. Improved intestinal absorption and reduced PS requirements were generally maintained in the longer term. Results from a phase III trial in paediatric patients with SBS-IF dependent on PS were consistent with those in adults. Adverse events were mostly of mild to moderate severity and generally consistent with the underlying condition or known mechanism of the drug (e.g. central line-related issues, gastrointestinal events). Teduglutide is therefore a useful treatment option in children (aged ≥1 year), adolescents and adults with SBS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. O’Keefe SJD, Buchman AL, Fishbein TM, et al. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol. 2006;4(1):6–10.

    Article  PubMed  Google Scholar 

  2. Jeppesen PB. Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure. J Parenter Enter Nutr. 2014;38(1 Suppl):8S–13S.

    Article  Google Scholar 

  3. National Institute of Diabetes and Digestive and Kidney Diseases. Short bowel syndrome. 2015. https://www.niddk.nih.gov. Accessed 18 Jan 2017.

  4. Vanderhoof JA, Pauley-Hunter R. Short-bowel syndrome. In: Guandalini S, Dhawan A, Branski D, editors. Textbook of pediatric gastroenterology, hepatology and nutrition: a comprehensive guide to practice. Cham: Springer International Publishing; 2016. p. 495–503.

    Chapter  Google Scholar 

  5. Pironi L, Arends J, Bozzetti F, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. 2016;35(2):247–307.

    Article  PubMed  Google Scholar 

  6. Tappenden KA. Pathophysiology of short bowel syndrome: considerations of resected and residual anatomy. J Parenter Enter Nutr. 2014;38(1 Suppl):14S–22S.

    Article  CAS  Google Scholar 

  7. Tappenden KA. Intestinal adaptation following resection. J Parenter Enter Nutr. 2014;38(Suppl 1):23S–31S.

    Article  Google Scholar 

  8. NPS Pharma Holdings Limited. Revestive (teduglutide) 5 mg powder and solvent for solution for injection: EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 31 Jan 2017.

  9. McMellen ME, Wakeman D, Longshore SW, et al. Growth factors: possible roles for clinical management of the short bowel syndrome. Semin Pediatr Surg. 2010;19(1):35–43.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jeppesen PB. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. J Parenter Enter Nutr. 2014;38(1 Suppl):45S–52S.

    Article  CAS  Google Scholar 

  11. Kelly DG, Tappenden KA, Winkler MF. Short bowel syndrome: highlights of patient management, quality of life, and survival. J Parenter Enter Nutr. 2014;38(4):427–37.

    Article  Google Scholar 

  12. Burness CB, McCormack PL. Teduglutide: a review of its use in the treatment of patients with short bowel syndrome. Drugs. 2013;73(9):935–47.

    Article  CAS  PubMed  Google Scholar 

  13. McKeage K. Teduglutide: a guide to its use in short bowel syndrome. Clin Drug Invest. 2015;35(5):335–40.

    Article  CAS  Google Scholar 

  14. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Tappenden KA, Edelman J, Joelsson B. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol. 2013;47(7):602–7.

    Article  CAS  PubMed  Google Scholar 

  16. Seidner DL, Joly F, Youssef NN. Effect of teduglutide, a glucagon-like peptide 2 analog, on citrulline levels in patients with short bowel syndrome in two phase III randomized trials. Clin Transl Gastroenterol. 2015. doi:10.1038/ctg.2015.15.

  17. Carter BA, Cohran VC, Cole CR, et al. Outcomes from a 12-week, open-label, multicenter clinical trial of teduglutide in pediatric short bowel syndrome. J Pediatr. 2016. doi:10.1016/j.jpeds.2016.10.027.

  18. Schwartz LK, O’Keefe SJD, Fujioka K, et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol. 2016. doi:10.1038/ctg.2015.69.

  19. O’Keefe SJD, Jeppesen PB, Gilroy R, et al. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol. 2013;11(7):815–23.e1-3.

  20. Hartmann M, Timmer W, Schultz A, et al. A thorough QT study of teduglutide in healthy subjects. Clin Pharmacol Drug Dev. 2012;1(2):57–66.

    CAS  PubMed  Google Scholar 

  21. Berg JK, Kim EH, Li B, et al. A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects. BMC Gastroenterol. 2014;14:25. doi:10.1186/1471-230X-14-25.

  22. Iturrino J, Camilleri M, Acosta A, et al. Acute effects of a glucagon-like peptide 2 analogue, teduglutide, on gastrointestinal motor function and permeability in adult patients with short bowel syndrome on home parenteral nutrition. J Parenter Enter Nutr. 2015. doi:10.1177/0148607115597644.

  23. European Medicines Agency. Revestive-H-C-2345-II-20: EPAR assessment report-variation. 2016. http://www.ema.europa.eu. Accessed 31 Jan 2017.

  24. Nave R, Halabi A, Herzog R, et al. Pharmacokinetics of teduglutide in subjects with renal impairment. Eur J Clin Pharmacol. 2013;69(5):1149–55.

    Article  CAS  PubMed  Google Scholar 

  25. European Medicines Agency. Revestive: EPAR-public assessment report. 2012. http://www.ema.europa.eu. Accessed 31 Jan 2017.

  26. Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473–81.e3.

  28. Iyer K, Fujioka K, Boullata JI, et al. Safety and efficacy of long-term teduglutide treatment for patients with short bowel syndrome and intestinal failure: final results of the steps-3 study [abstract no. OP350]. United Eur Gastroenterol J. 2014;2(1 Suppl):A111.

    Google Scholar 

  29. Fujioka K, Schneider SM, Li B, et al. Teduglutide, a recombinant analog of GLP-2, reduces parenteral support in patients with short bowel syndrome regardless of ultra-short remnant bowel and/or no colon-in-continuity anatomy [abstract no. 190]. Transplantation. 2015;99(6 Suppl):S27.

    Google Scholar 

  30. Jeppesen PB, Pertkiewicz M, Forbes A, et al. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide–analyses from a randomised, placebo-controlled study. Clin Nutr. 2013;32(5):713–21.

    Article  CAS  PubMed  Google Scholar 

  31. Iyer KR, Kunecki M, Boullata JI, et al. Independence from parenteral nutrition and intravenous fluid support during treatment with teduglutide among patients with intestinal failure associated with short bowel syndrome. J Parenter Enter Nutr. 2016. doi:10.1177/0148607116680791.

  32. Youssef NN, Pape U-F, Delmaestro E, et al. Long-term safety of teduglutide treatment for patients with intestinal failure associated with short bowel syndrome [abstract no. 1763]. Am J Gastroenterol. 2015;110(Suppl 1):S749–50.

    Google Scholar 

  33. Jeppesen PB, Boullata JI, Ziegler TR, et al. Independence from parenteral support achieved with teduglutide treatment in patients with intestinal failure associated with short bowel syndrome [abstract no. PP131-SUN]. Clin Nutr. 2014;33(Suppl 1):S68–9.

    Article  Google Scholar 

  34. Fujioka K, Jeejeebhoy K, Pape UF, et al. Patients with short bowel on narcotics during 2 randomized trials have abdominal complaints independent of teduglutide. J Parenter Enter Nutr. 2016. doi:10.1177/0148607116663481.

  35. Shire. Shire receives extension of market authorization in Europe for Revestive® (teduglutide) for the treatment of paediatric patients with short bowel syndrome (SBS) [media release]. 7 July 2016. https://www.shire.com.

  36. Compher C, Boullata JI, Pickett-Blakely O, et al. Clinical management of patients with parenteral nutrition-dependent short bowel syndrome during teduglutide therapy. J Parenter Enter Nutr. 2015. doi:10.1177/0148607115594010.

  37. Kochar B, Long MD, Shelton E, et al. Safety and efficacy of teduglutide (Gattex) in patients with Crohn’s disease and need for parenteral support due to short bowel syndrome-associated intestinal failure. J Clin Gastroenterol. 2016. doi:10.1097/MCG.0000000000000604.

  38. Pevny S, Maasberg S, Karber M, et al. Analysis of treatment results with teduglutide on intestinal absorption and nutritional status in patients with short bowel syndrome [abstract no. P1636]. In: 24th UEG Week; 2016.

  39. Bowlin SJ, Youssef NN, Kim EH. Design and details of a prospective global short bowel syndrome patient population registry [abstract no. 1765]. Am J Gastroenterol. 2015;110(Suppl 1):S750.

    Google Scholar 

Download references

Acknowledgements

During the peer review process, the manufacturer of teduglutide was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Esther S. Kim & Susan J. Keam

Authors
  1. Esther S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Esther S. Kim.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Esther Kim and Susan Keam are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: S. Klek, General and Oncology Surgery Unit, Stanley Dudrick’s Memorial Hospital, Skawina, Poland; J. Nightingale, Intestinal Failure Unit, St. Mark’s Hospital, Harrow, UK; S. M. Schneider, Gastroenterology and Clinical Nutrition, University of Nice-Sophia Antipolis, Nice, France; D. L. Seidner, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, E.S., Keam, S.J. Teduglutide: A Review in Short Bowel Syndrome. Drugs 77, 345–352 (2017). https://doi.org/10.1007/s40265-017-0703-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-017-0703-7

Keywords

Search

Navigation